IFF:NYE-Internationa Flavors & Fragrances Inc.

EQUITY | Chemicals | New York Stock Exchange

Last Closing

USD 123.71

Change

-0.98 (-0.79)%

Market Cap

USD 9.58B

Volume

1.10M

Analyst Target

USD 145.27
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

International Flavors & Fragrances Inc is engaged in manufacturing and supplying of flavors and fragrances for the food, beverage, personal care and household products industries either in the form of compounds or individual ingredients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-25 )

Largest Industry Peers for Chemicals

Symbol Name Price(Change) Market Cap
DOW Dow Inc

+0.24 (+0.42%)

USD 42.26B
CE Celanese Corporation

-0.62 (-0.40%)

USD 18.14B
HUN Huntsman Corporation

-0.04 (-0.17%)

USD 4.46B
BAK Braskem SA Class A

-0.09 (-1.01%)

USD 3.54B
TROX Tronox Holdings PLC

+0.15 (+0.86%)

USD 2.56B
REX REX American Resources Corpora..

-0.84 (-1.48%)

USD 1.03B
WLKP Westlake Chemical Partners LP

+0.06 (+0.27%)

USD 0.77B
ASIX AdvanSix Inc

-0.53 (-1.95%)

USD 0.72B
LXU Lsb Industries Inc

-0.03 (-0.37%)

USD 0.62B
VHI Valhi Inc

-0.35 (-2.35%)

USD 0.46B

ETFs Containing IFF

VEGB:LSE VanEck Sustainable Future.. 4.86 % 0.00 %

-0.07 (0.00%)

USD 6.37M
IVEG iShares Emergent Food and.. 4.28 % 0.00 %

-0.12 (0.00%)

USD 4.79M
RTM Invesco S&P 500® Equal W.. 3.77 % 0.40 %

+0.05 (+0.00%)

USD 0.28B
RSPM Invesco S&P 500® Equal.. 3.71 % 0.00 %

+0.05 (+0.00%)

USD 0.29B
F4DE:XETRA Ossiam Food for Biodivers.. 3.70 % 0.00 %

-0.22 (0.00%)

USD 0.04B
F4DU:XETRA Ossiam Food for Biodivers.. 3.70 % 0.00 %

-0.29 (0.00%)

USD 7.14M
PBI:CA Purpose Best Ideas 3.49 % 0.79 %

-0.35 (0.00%)

CAD 0.01B
IYM iShares U.S. Basic Materi.. 3.08 % 0.00 %

+0.13 (+0.00%)

USD 0.65B
MOAT:AU VanEck Morningstar Wide M.. 2.60 % 0.00 %

-0.06 (0.00%)

USD 0.93B
MHOT:AU VanEck Morningstar Wide M.. 2.59 % 0.00 %

N/A

N/A
SDOG ALPS Sector Dividend Dogs.. 2.15 % 0.40 %

+0.26 (+0.00%)

USD 1.12B
LGBT 1.44 % 0.00 %

N/A

N/A
JHMA 0.00 % 0.47 %

N/A

N/A
MOAT 0.00 % 0.49 %

N/A

N/A
FOANC 0.00 % 0.00 %

N/A

N/A
PEXL Pacer US Export Leaders E.. 0.00 % 0.60 %

+0.19 (+0.00%)

USD 0.06B
SZNE Pacer CFRA-Stovall Equal .. 0.00 % 0.60 %

+0.05 (+0.00%)

USD 0.04B
UXM.A:CA 0.00 % 1.49 %

N/A

N/A
XSPX:SW Xtrackers S&P 500 Swap UC.. 0.00 % 0.00 %

+0.60 (+0.00%)

USD 5.05B
DIET 0.00 % 0.00 %

N/A

N/A
WMTS:SW iShares MSCI World Materi.. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Chemicals) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.86% 5% F 6% D-
Dividend Return 0.54% 39% F 33% F
Total Return -7.32% 5% F 6% D-
Trailing 12 Months  
Capital Gain -6.70% 55% F 33% F
Dividend Return 2.17% 54% F 37% F
Total Return -4.53% 53% F 32% F
Trailing 5 Years  
Capital Gain 32.51% 74% C 75% C
Dividend Return 12.87% 63% D 45% F
Total Return 45.38% 79% B- 72% C
Average Annual (5 Year Horizon)  
Capital Gain 7.79% 58% F 75% C
Dividend Return 9.77% 55% F 74% C
Total Return 1.98% 46% F 40% F
Risk Return Profile  
Volatility (Standard Deviation) 12.03% 87% B+ 59% D-
Risk Adjusted Return 81.22% 89% A- 78% C+
Market Capitalization 9.58B 87% B+ 89% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Chemicals) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.90 20% 17%
Price/Book Ratio 3.27 51% 22%
Price / Cash Flow Ratio 6.24 11% 15%
Price/Free Cash Flow Ratio 47.40 9% 9%
Management Effectiveness  
Return on Equity 9.93% 24% 59%
Return on Invested Capital 9.11% 22% 53%
Return on Assets 4.23% 36% 65%
Debt to Equity Ratio 95.00% 57% 40%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector